- Home
- SAIH vs SABS Comparison
SAIH vs SABS Comparison
Compare SAIH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- SABS
- Stock Information
- Founded
- SAIH 2019
- SABS 2014
- Country
- SAIH Singapore
- SABS United States
- Employees
- SAIH N/A
- SABS N/A
- Industry
- SAIH
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- SAIH
- SABS Health Care
- Exchange
- SAIH NYSE
- SABS Nasdaq
- Market Cap
- SAIH 20.0M
- SABS 19.0M
- IPO Year
- SAIH N/A
- SABS N/A
- Fundamental
- Price
- SAIH $0.68
- SABS $1.82
- Analyst Decision
- SAIH
- SABS Strong Buy
- Analyst Count
- SAIH 0
- SABS 5
- Target Price
- SAIH N/A
- SABS $12.40
- AVG Volume (30 Days)
- SAIH 111.6K
- SABS 246.2K
- Earning Date
- SAIH 11-13-2024
- SABS 03-28-2025
- Dividend Yield
- SAIH N/A
- SABS N/A
- EPS Growth
- SAIH N/A
- SABS N/A
- EPS
- SAIH N/A
- SABS N/A
- Revenue
- SAIH $6,954,000.00
- SABS $1,512,723.00
- Revenue This Year
- SAIH N/A
- SABS N/A
- Revenue Next Year
- SAIH N/A
- SABS N/A
- P/E Ratio
- SAIH N/A
- SABS N/A
- Revenue Growth
- SAIH N/A
- SABS N/A
- 52 Week Low
- SAIH $0.54
- SABS $1.60
- 52 Week High
- SAIH $1.80
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- SABS 36.28
- Support Level
- SAIH N/A
- SABS $2.00
- Resistance Level
- SAIH N/A
- SABS $2.15
- Average True Range (ATR)
- SAIH 0.00
- SABS 0.20
- MACD
- SAIH 0.00
- SABS 0.03
- Stochastic Oscillator
- SAIH 0.00
- SABS 30.99
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the advanced Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, advanced liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.